Company Continues Innovation with a Collaboration with
Yale University to Explore Human Health
Applications and an Expanded Database of Kidney Information
WESTBROOK, Maine, Jan. 8, 2018 /PRNewswire/ -- IDEXX
Laboratories, Inc. (NASDAQ: IDXX) today announced that the IDEXX
Catalyst® SDMA Test will be commercially available to
all North American customers on January 16,
2018, enabling IDEXX's point-of-care customers to add SDMA
as an essential element of the routine chemistry panel.
As part of IDEXX's launch ramp of this advanced kidney test for
the point of care, more than 2,731 preorders for the 12-test box of
the Catalyst SDMA Test have already been shipped to IDEXX
customers, and another 1,762 existing preorders are expected to be
shipped this week. The Catalyst SDMA Test has been in use in
hundreds of practices across the United
States since December, advancing veterinary healthcare and
patient outcomes. The Catalyst SDMA Test can be added to any
chemistry panel on IDEXX's Catalyst One® and Catalyst
Dx® chemistry analyzers as part of the patient sample
run, with the full chemistry panel results, including SDMA,
available within minutes.
IDEXX expects to bring the Catalyst SDMA Test to customers
beyond the U.S. and Canada over
the course of the next several months. There are currently more
than 28,000 Catalyst One and Catalyst Dx analyzers in use in
veterinary practices worldwide.
Additionally, to further explore SDMA's potential applications
to human health, IDEXX has signed a collaboration agreement with
Yale University. As part of this
partnership with a world-leading human nephrology research
organization, the IDEXX SDMA® Test was validated for
accuracy in measuring SDMA in human blood samples, and the results
were presented at the 2017 annual meeting of the American Society
of Nephrology last November by Yale and
IDEXX researchers. Future research with Yale will focus on the clinical utility of SDMA in
human patients using the validated IDEXX SDMA Test.
IDEXX first launched the IDEXX SDMA Test at its reference
laboratories in 2015, and has run more than 12 million SDMA patient
tests, creating the world's largest database on kidney disease in
dogs and cats. The IDEXX SDMA Test is a kidney test proven to
identify kidney disease earlier than creatinine,1–3
enabling veterinarians to intervene earlier to meaningfully impact
a patient's health outcomes and quality of life. Whether the kidney
condition is chronic, acute, or a secondary consequence of other
common diseases found in veterinary medicine, SDMA provides the
unique opportunity to gain important insight into the health of
sick or seemingly healthy patients alike—and take action
earlier.
"We've seen great enthusiasm for the ability to run SDMA as part
of the routine chemistry panel at the point of care, and preorders
have exceeded our expectations," said Jonathan Ayers, Chairman and Chief Executive
Officer of IDEXX Laboratories. "The IDEXX SDMA Test represents one
of the most significant diagnostic innovations in veterinary
medicine in the last 30 years. We're thrilled to bring this
essential element of the chemistry panel to our point of care IDEXX
VetLab® suite, allowing veterinarians to utilize the
benefits of SDMA immediately during the pet's appointment."
"SDMA has tremendous potential benefit in human applications as
well," Ayers continued. "And with the IDEXX test technology now
validated to be able to run on commercial chemistry systems that
routinely produce chemistry results in human reference
laboratories, we have greater reason to explore the clinical value
of this incredible biomarker in human applications. We are excited
and grateful for our partnership with Yale
University."
SDMA is the subject of more than 30 ongoing research
collaborations and has been incorporated into the veterinary
profession's International Renal Interest Society (IRIS) kidney
disease staging guidelines. This underscores IDEXX's leadership in
the renal market in the veterinary field and shows that the IDEXX
SDMA Test is becoming commonly appreciated as an essential element
of the routine chemistry panel.
For more information about the IDEXX Catalyst SDMA Test, visit
www.idexx.com/catalystsdma.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a
member of the S&P 500® Index and is a leader in pet
healthcare innovation, serving practicing veterinarians around the
world with a broad range of diagnostic and information
technology-based products and services. IDEXX products enhance the
ability of veterinarians to provide advanced medical care, improve
staff efficiency and build more economically successful practices.
IDEXX is also a worldwide leader in providing diagnostic tests and
information for livestock and poultry and tests for the quality and
safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than
7,000 people and offers products to customers in over 175
countries. For more information about IDEXX, visit
www.idexx.com.
Note Regarding Forward-Looking Statements
This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," and similar
words and expressions. These forward-looking statements are based
on management's current expectations and beliefs, as well as a
number of assumptions concerning future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results,
performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. IDEXX
assumes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Readers are advised to review IDEXX's filings with the
United States Securities and Exchange Commission (which are
available from the SEC's EDGAR database
at sec.gov and via IDEXX's website
at idexx.com).
References
- Nabity MB, Lees GE, Boggess M, Yerramilli M, Obare E,
Yerramilli M, Rakitin A, Aguiar J, Relford R. Symmetric
dimethylarginine assay validation, stability, and evaluation as a
marker for early detection of chronic kidney disease in dogs. J
Vet Intern Med. 2015;29(4):1036–1044.
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE.
Comparison of serum concentrations of symmetric dimethylarginine
and creatinine as kidney function biomarkers in cats with chronic
kidney disease. J Vet Intern Med. 2014;28(6):1676–1683.
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell
DE. Serum concentrations of symmetric dimethylarginine and
creatinine in dogs with naturally occurring chronic kidney disease.
J Vet Intern Med. 2016;30(3):794–802.
CONTACTS:
Media Relations
Robin Woodcock
207-632-8027
robin-woodcock@idexx.com
Investor Relations
Kerry Bennett
207-556-8155
kerry-bennett@idexx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/idexx-launches-sdma-in-the-point-of-care-with-idexx-catalyst-sdma-test-300578303.html
SOURCE IDEXX Laboratories, Inc.